In this study, GLP1-RAs did not reduce advanced therapies or corticosteroid initiation, although sensitivity analysis showed benefits of GLP1-RAs in reducing corticosteroid initiation in patients with and without obesity. The gene discussed is GLP1R; the disease is obesity disorder.